Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare genetic disorders. The company is particularly focused on conditions such as Prader-Willi syndrome, and their lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, is currently in Phase 3 clinical trials. Soleno is inspired by the needs of patients and families living with rare diseases and aims to deliver effective treatment options to enhance their quality of life. The company is dedicated to advancing research and developing treatments for diseases with unmet medical needs, thereby contributing to shareholder value while improving patient outcomes.